AzTrials
AzTrials

Chronic Non-specific Low Back PainTLF-MFR-LBPNCT07667062

Effects of Thoracolumbar Fascia Myofascial Release in Chronic Low Back Pain

A study testing Myofascial Release of Thoracolumbar Fascia in people with Chronic Non-specific Low Back Pain, run by University of Health Sciences Lahore at 1 site in Pakistan.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The thoracolumbar fascia (TLF) is thickened and stiffer in individuals with chronic non-specific low back pain (CNSLBP) and may contribute to pain persistence. Myofascial release (MFR) has been shown to reduce TLF stiffness acutely; however, its longer-term effects on fascial morphology and pain self-efficacy remain… Read more about this study

Who is it for?
Ages 18 to 60 years
Conditions the study is for
Chronic Non-specific Low Back Pain
What is being tested?
Myofascial Release of Thoracolumbar Fascia
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
65 participants
Where
1 sitePakistan
Study dates
20 Jun 2026to Aug 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Adults aged 18-60 years
  • Non-specific low back pain duration > 12 weeks
  • Average pain intensity NRS ≥ 3 over the past week
  • Able to provide written informed consent
  • Able to attend 18 supervised sessions over 6 weeks (3 sessions/week)

Who cannot join

  • Specific spinal pathology (fracture, disc herniation with neurological deficit, spinal stenosis, inflammatory arthropathy, malignancy)
  • Previous lumbar surgery
  • Current pregnancy
  • Severe psychiatric disorder or active psychosis
  • Manual therapy or physiotherapy for LBP within the previous 3 months
  • Systemic connective tissue disorder (e.g., Ehlers-Danlos syndrome, Marfan syndrome)
  • Contraindication to ultrasound imaging or manual therapy.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Manahil Nisar, DPT contact

03240691766

dr.manahilnisar@gmail.com

Pakistan1 site
  • Affiliated Teaching Hospitals of University of Health Sciences Lahore

    Lahore, Punjab Province

    Manahil Nisar, DPT, dr.manahilnisar@gmail.com

    dr.manahilnisar@gmail.com

Other trials in Pakistan

About this study

Official title: Effects of Myofascial Release Targeting the Thoracolumbar Fascia on Fascial Morphology, Functional Outcomes, and Pain Self-Efficacy in Adults With Chronic Non-Specific Low Back Pain: A Randomized Controlled Trial

The thoracolumbar fascia (TLF) is thickened and stiffer in individuals with chronic non-specific low back pain (CNSLBP) and may contribute to pain persistence. Myofascial release (MFR) has been shown to reduce TLF stiffness acutely; however, its longer-term effects on fascial morphology and pain self-efficacy remain unclear. This randomized controlled trial will investigate the effects of a standardized 6-week MFR program targeting the thoracolumbar fascia compared with sham MFR in adults with CNSLBP. A total of 65 participants aged 18-60 years with CNSLBP will be randomized in a 1:1 ratio to either standardized MFR or sham MFR. The intervention will consist of 18 treatment sessions delivered over 6 weeks. Primary outcomes include thoracolumbar fascia thickness measured by B-mode ultrasound, thoracolumbar fascia stiffness measured by shear-wave elastography, and pain self-efficacy measured using the Pain Self-Efficacy Questionnaire (PSEQ). Secondary outcomes include pain intensity, functional disability, lumbar flexion range of motion, and patient global impression of change. Outcomes will be assessed at baseline and after completion of the 6-week intervention period.

Read the detailed description

Chronic non-specific low back pain (CNSLBP) is associated with structural and mechanical alterations of the thoracolumbar fascia (TLF), including increased thickness and stiffness. These changes may contribute to persistent pain and functional limitations. Myofascial release (MFR) is a manual therapy intervention designed to improve fascial mobility and reduce tissue stiffness; however, its effects on TLF morphology and related clinical outcomes remain incompletely understood.

This randomized controlled trial will evaluate the effects of a standardized 6-week myofascial release program targeting the thoracolumbar fascia in adults with chronic non-specific low back pain. Participants will be randomly assigned in a 1:1 ratio to either a myofascial release group or a sham myofascial release group.

Primary outcomes include thoracolumbar fascia thickness measured using B-mode ultrasound, thoracolumbar fascia stiffness measured using shear-wave elastography, and pain self-efficacy measured using the Pain Self-Efficacy Questionnaire. Secondary outcomes include pain intensity, disability, lumbar flexion range of motion, and patient global impression of change. Assessments will be performed at baseline and after completion of the 6-week intervention period.

The study aims to determine whether targeted myofascial release can modify thoracolumbar fascia morphology and improve clinical and psychosocial outcomes in individuals with chronic non-specific low back pain.

Being tested
Myofascial Release of Thoracolumbar Fascia, Sham Myofascial Release
Keywords
Thoracolumbar fascia, Myofascial release, Chronic low back pain, Fascia thickness, Fascial stiffness, Pain self-efficacy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Myofascial Release of Thoracolumbar FasciaBehavioural

    Also called Crossed-hands Myofascial Release, Thoracolumbar Fascial Release, Manual Fascial Therapy

    Standardized myofascial release targeting the thoracolumbar fascia will be administered over 18 sessions across 6 weeks (3 sessions per week). Each session will last approximately 40 minutes and will involve sustained low-load manual pressure using a crossed-hands technique applied bilaterally at L2-L3 and L4-L5 regions. The intervention aims to reduce fascial stiffness and improve tissue mobility. Treatment will be delivered by a trained physiotherapist following a standardized protocol. No additional physiotherapy interventions will be provided during the study period

  • Sham Myofascial ReleaseOther

    Also called Placebo manual therapy, Light touch intervention, Sham fascial release

    Sham myofascial release will be applied over the same anatomical regions as the experimental group using light manual contact (<50 g force) without therapeutic pressure or fascial engagement. Sessions will be matched in duration (approximately 40 minutes), frequency (3 sessions per week), and total duration (6 weeks, 18 sessions). The aim is to control for placebo effects, therapist attention, and patient expectation

Study groups in NCT07667062
Study groupRoleWhat they receive
Myofascial Release GroupExperimentalParticipants in this group will receive standardized myofascial release targeting the thoracolumbar fascia. The intervention will consist of 18 sessions over 6 weeks (3 sessions per week), each lasting approximately 40 minutes. The technique involves sustained low-load manual pressure using a crossed-hands approach applied to bilateral L2-L3 and L4-L5 regions of the thoracolumbar fascia. Treatment will be delivered by a trained physiotherapist following a standardized protocol. No additional physiotherapy interventions will be provided during the study period
Receives: Behavioral: Myofascial Release of Thoracolumbar Fascia
Sham Myofascial Release GroupSham comparatorParticipants in this group will receive sham myofascial release targeting the same anatomical regions as the experimental group. Light manual contact (<50 g force) will be applied without therapeutic pressure or fascial engagement. The session duration and frequency will be identical to the experimental group (18 sessions over 6 weeks, 3 sessions per week, approximately 40 minutes per session). Participants will receive identical positioning and therapist contact time to control for placebo and attention effects.
Receives: Other: Sham Myofascial Release

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Thoracolumbar Fascia Thickness

    Change in thoracolumbar fascia thickness measured using B-mode ultrasound imaging

    Measured: Baseline and 6 weeks

  2. Thoracolumbar Fascia Stiffness

    Change in thoracolumbar fascia stiffness measured using shear-wave Sonoelastography.

    Measured: Baseline and 6 weeks

  3. Pain Self-Efficacy (PSEQ)

    Change in pain self-efficacy measured using the Pain Self-Efficacy Questionnaire (PSEQ), a 10-item questionnaire assessing confidence in performing activities despite pain. Total scores range from 0 to 60, with higher scores indicating better pain self-efficacy (greater confidence in functioning despite pain).

    Measured: Baseline and 6 weeks

Secondary outcomes (4)
  1. Pain Intensity (Numeric Rating Scale)

    Change in pain intensity measured using the 11-point Numeric Rating Scale (NRS), with scores ranging from 0 (no pain) to 10 (worst imaginable pain).

    Measured: Baseline and 6 weeks

  2. Functional Disability (Oswestry Disability Index)

    Functional disability will be assessed using the Oswestry Disability Index (ODI). Total scores range from 0 to 100, with higher scores indicating greater disability (worse functional status)

    Measured: Baseline and 6 weeks

  3. Lumbar Flexion Range of Motion

    Change in lumbar flexion range of motion measured using the Modified Schober Test.

    Measured: Baseline and 6 weeks

  4. Patient Global Impression of Change (PGIC)

    Participant-reported overall perception of improvement following the intervention, assessed using the Patient Global Impression of Change (PGIC) scale. The PGIC is a 7-point scale ranging from 1 to 7, where 1 = very much worse and 7 = very much improved. Higher scores indicate greater perceived improvement and a better outcome

    Measured: 6 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jun 2026
  2. Study start20 Jun 2026 (estimated)
  3. Primary completionAug 2026 (estimated)
  4. Study completionAug 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a two-arm, parallel-group randomized controlled trial in which participants will be allocated in a 1:1 ratio to either a standardized myofascial release intervention targeting the thoracolumbar fascia or a sham myofascial release control group. Outcomes will be assessed at baseline and post-intervention.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
65 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07667062
Sponsor's protocol ID
UHS/USERC-26/SEC/480
Acronym
TLF-MFR-LBP
Status last verified
Jun 2026
First submitted
18 Jun 2026
Last updated
26 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be shared. Data will be retained by the investigators and institution in accordance with ethical and confidentiality requirements

Publications

  • Devantery K, Morin M, Grimard J, Gaudreault N. Effects of a Myofascial Technique on the Stiffness and Thickness of the Thoracolumbar Fascia and Lumbar Erector Spinae Muscles in Adults with Chronic Low Back Pain: A Randomized before-and-after Experimental Study. Bioengineering (Basel). 2023 Mar 6;10(3):332. doi: 10.3390/bioengineering10030332.

    PubMed 36978723

Questions about this trial

What is this clinical trial studying?

A study testing Myofascial Release of Thoracolumbar Fascia in people with Chronic Non-specific Low Back Pain, run by University of Health Sciences Lahore at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 26 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Manahil Nisar, DPT (03240691766, dr.manahilnisar@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Thoracolumbar Fascia Thickness (time frame: Baseline and 6 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07667062, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in